While the primary use for 3D printers still appears to be arts and crafts, one B.C. company is using them to combat one of the world’s fastest-growing diseases.
What happened: Vancouver biotech startup Aspect Biosystems raised US$115 million as it pursues human testing of its sci-fi-sounding 3D-printed human tissue technology that could revolutionize diabetes treatment. The most eye-catching investor is drug giant Novo Nordisk.
- It’s not the first time the two have linked up: the Wegovy maker inked a deal with Aspect in 2023 for a stake and an exclusive global licence to use its tech to develop up to four new products. The ongoing deal could be worth as much as US$2.6 billion.
How it works: Aspect designs implants made of stem cells and proteins that are 3D-printed and implanted into the body to help organs function better. In the case of treating diabetes, implants into the liver or pancreas would improve insulin production.
Why it matters: Multiple researchers are developing cell replacement therapy for diabetes, but Aspect is one of the most promising, already successfully treating diabetes in rodents. If it works for humans and can be scaled up, it could do away with daily insulin shots for some patients.—QH
